| 開催日 | 2026年9月8日(火) |
|---|---|
| 開催地 | Web |
Date & Time
Date: September 8, 2026
Time: 10:30am IST, 1:00pm SGT, 2:00pm KST, 3:00pm AEST, 6:00pm NZDT
Abstract Understanding the tissue microenvironment in tumour samples is an important factor for predicting response to different treatment regimens. Highly multiplexed imaging of tenfolds of protein markers can help to define this complex biology. However, these assays are costly and not always easy to scale for larger translational studies that are often needed to translate findings to clinical evidence. In this webinar, we demonstrate how we move from a highly multiplexed imaging platform used in a discovery phase to identify a marker for response prediction to immunotherapy at the translational phase. This transition was possible with the use of the Invitrogen™ EVOS™ S1000 Spatial Imaging System in combination with the Invitrogen™ Aluora™ Spatial Amplification Kits and a panel of 6 markers. By focusing on the most relevant targets from the discovery panel, the cost per sample is reduced to about 25 % of the initial assay, thereby resulting in a more affordable option for larger translational cohort studies. In addition, we show how relevant protein markers can be combined with in situ proximity Ligation Assay (is PLA) to simultaneously look at protein interactions, in this case demonstrated for PD-1/PD-L1. In summary, this workflow enables scalable, cost-effective spatial biology approaches that bridge discovery and clinical translation. Learning Objectives:
・Learn how to transition from discovery to translational proteomic imaging assays
・Understand how spectral imaging with the EVOS S1000 Spatial Imaging System can be used for hypothesis-driven research
・Explore the use of spatial amplification reagents for exploring the tissue microenvironment
